Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DestinationRx introduces mobile DrugCompare tool
The mobile version aids consumers to access therapeutic alternative database and allows to view and compare prescription drug savings and safety information at the point of prescription. Mobile
The mobile version aids consumers to access therapeutic alternative database and allows to view and compare prescription drug savings and safety information at the point of prescription. Mobile
With this new agreement, both the parties have made changes to the previous agreement signed in 2006. The new deal has an initial term ending on 31 December
The changes were made based on a request from Ministry of Health, Labor and Welfare for development of new dosages of Pasetocin. Pasetocin is a broad spectrum antibiotic
Febuxostat is indicated as a treatment for gout and hyperuricemia. The agreement allows Astellas Pharma to sell the product in India, Indonesia, Thailand, the Philippines, Malaysia, Vietnam and
Under the contract, the companies will explore the usage of Anacor’s boron chemistry to discover products for a variety of animal health applications. The research is funded by
The agency plans to complete the whole review process by the date for Bydureon, an experimental medication for type 2 diabetes. Earlier, Amylin and Lilly partnered to develop
Currently, Nyloxin is available as an oral spray in US for joint pain, back pain, neck aches, migraines, headaches and neuralgia and as atopical gel to treat arthritis
Complera, which mixes three antiretroviral medications in one daily tablet, contains Gilead‘s Truvada and Tibotec Pharmaceuticals’ non-nucleoside reverse transcriptase inhibitor, rilpivirine. The FDA approval is supported by the
The trial will evaluate the HIV patients who are using MVA85A, which is being developed by OETC, a joint venture between the University of Oxford and Emergent BioSolutions,
The company’s loss from operations for the second quarter of 2011 was $6.58m, compared to $4.3m for the same period in 2010. For the six months ended 30